BioTrends Research Group Finds 43% Rise in Biologics as Crohn's Treatment

A study conducted by the BioTrends Research Group found a 43 percent increase of biologic treatments in Crohn's Disease patients in remission since 2012, according to a Genetic Engineering & Biotechnology News report.

Certolizumab and adalimumab are the two most noteworthy biologics behind this recent rise in biologic treatments for Crohn's patients in remission, but infliximab remains the most prevalent biologic treatment for Crohn's Disease on the market.

More Articles on Gastroenterology:

Columbus Regional Health Opens $3.8M Endoscopy Center
How Much do Gastroenterologist Make? 27 Statistics
Swallow Solutions Launches Dysphagia Treatment Device

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Webinars

Featured Whitepapers

Featured Podcast